C2 (Complement Component 2)

Migration, Crosslink

📖

C2 (Complement Component 2)

active

wiki page Created: 2026-04-02T07:19:16 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-c2

📖 Wiki Page

gene1670 wordssynced 2026-04-02

C2 (Complement Component 2)

| Property | Value | [@ricklin2013] |
|----------|-------| [@merle2015] |
| Gene Symbol | C2 |
| Full Name | Complement Component 2 |
| Chromosomal Location | 6p21.3 (MHC Class III) |
| NCBI Gene ID | 717 |
| OMIM ID | 120490 |
| Ensembl ID | ENSG00000166278 |
| UniProt ID | P06610 |
| Encoded Protein | Complement component C2 |
| Associated Diseases | Alzheimer's Disease, Age-Related Macular Degeneration, Systemic Lupus Erythematosus, Complement Deficiency |

</div>

Overview

...

C2 (Complement Component 2)

| Property | Value | [@ricklin2013] |
|----------|-------| [@merle2015] |
| Gene Symbol | C2 |
| Full Name | Complement Component 2 |
| Chromosomal Location | 6p21.3 (MHC Class III) |
| NCBI Gene ID | 717 |
| OMIM ID | 120490 |
| Ensembl ID | ENSG00000166278 |
| UniProt ID | P06610 |
| Encoded Protein | Complement component C2 |
| Associated Diseases | Alzheimer's Disease, Age-Related Macular Degeneration, Systemic Lupus Erythematosus, Complement Deficiency |

</div>

Overview

Mermaid diagram (expand to render)

C2 (Complement Component 2) is a crucial protein in the [classical complement pathway](/mechanisms/complement-system), representing one of the central activation mechanisms of the complement system—a major component of the [innate immune response](/mechanisms/innate-immune-signaling). Located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, the C2 gene encodes a 732-amino acid zymogen that, upon activation, generates the C3 convertase complex essential for complement cascade amplification.

The complement system, discovered in the late 19th century, constitutes a sophisticated network of soluble and membrane-bound proteins that bridge innate and adaptive immunity. C2, alongside its partner [C4](/genes/c4), forms the enzymatic core of the classical pathway, producing the critical C4b2a complex that cleaves [C3](/genes/c3) into active fragments. This positioning makes C2 a pivotal regulator of inflammation, opsonization, and cell lysis.

Beyond its fundamental immunological functions, C2 has emerged as a protein of significant interest in [neurodegenerative diseases](/diseases/alzheimers-disease), particularly [Alzheimer's Disease](/diseases/alzheimers-disease), where complement activation contributes to [neuroinflammation](/mechanisms/neuroinflammation), synaptic loss, and disease progression. Additionally, genetic variants in the C2 gene region have been associated with [age-related macular degeneration](/diseases/age-related-macular-degeneration) (AMD), highlighting its importance in both ocular and neurological disease contexts.

Gene Structure and Evolution

The C2 gene is located in the MHC class III region of chromosome 6p21.3 (positions 31,900,000-31,950,000, GRCh38) on the minus strand. This region, highly enriched for immune-related genes, also contains [C4](/genes/c4), factor B ([CFB](/genes/cfb)), and various other complement components. The gene spans approximately 18 kb and comprises 18 exons that encode a 732-amino acid protein with a molecular weight of approximately 83 kDa.

Protein Structure

Complement component C2 is synthesized as a single-chain zymogen comprising multiple functional domains:

N-terminal domain (aa 1-290): Variable region, heavy chain

MCP-like domain (aa 291-450): Protein-protein interactions

CCP domains (3) (aa 451-560): Complement control protein modules

C-terminal serine protease domain (aa 561-732): Catalytic activity (C2a fragment)

Upon activation, C2 is cleaved to form:

C2a (heavy chain, aa 1-427): Remains bound to C4b
C2b (light chain, aa 428-732): Released fragment with catalytic activity

Evolutionary Conservation

C2 shows conservation across vertebrates, reflecting its essential immune function:

| Species | Gene Name | Amino Acids | Identity |
|---------|-----------|-------------|----------|
| Human | C2 | 732 | Reference |
| Mouse | C2 | 733 | 72% |
| Zebrafish | c2 | 741 | 48% |
| Chicken | C2 | 728 | 69% |

The C2/C4 system shows gene duplication in evolution, with distinct but overlapping functions.

Protein Function and Activation

Classical Pathway Activation

The classical complement pathway is initiated by antigen-antibody complexes or pathogen-associated molecular patterns (PAMPs):

Step 1: C1qrs → C1s activation
Step 2: C1s cleaves C4 → C4a + C4b
Step 3: C1s cleaves C2 → C2a + C2b
Step 4: C4b + C2a → C4b2a (C3 convertase)
Step 5: C3 convertase cleaves C3 → C3a + C3b
Step 6: C3b deposition → opsonization, C5 convertase formation

C3 Convertase Function

The C4b2a complex (C3 convertase) represents a critical amplification step:

Catalytic activity: Rapidly cleaves multiple C3 molecules
Stability: Relatively short half-life (~2 minutes in plasma)
Regulation: Controlled by [C1-INH](/genes/serping1), [C4BP](/genes/c4bpa), [factor I](/genes/cfi)

C4b2b Distinction

It is crucial to distinguish the classical pathway C3 convertase from the [lectin pathway](/mechanisms/complement-system) C3 convertase:

Classical pathway: C4b2a (C2a fragment)
Lectin pathway: C4b2b (C2b fragment)

Normal Physiological Functions

Immune Defense

C2 supports fundamental immune functions [@janeway2016]:

Pathogen Recognition and Elimination

Opsonization: C3b generated downstream promotes phagocytosis
Cell lysis: Terminal membrane attack complex (MAC) formation
Inflammation: C3a and C5a as anaphylatoxins recruit immune cells

Bridge to Adaptive Immunity

Antigen presentation: C3b enhances antigen uptake by APCs
B cell activation: Complement receptors on B cells enhance responses
Immunological memory: C3d as adjuvant for antibody responses

Tissue Homeostasis

Beyond infection, complement participates in:

Dead cell clearance: Engulfment of apoptotic cells
Tissue remodeling: Proteolytic cascade in development
Angiogenesis: Modulation of blood vessel formation

Disease Associations

Alzheimer's Disease

C2 has significant involvement in [Alzheimer's Disease](/diseases/alzheimers-disease) pathogenesis [@gold2006]:

Complement Activation in AD

Amyloid-driven activation:

[β-amyloid](/proteins/amyloid-beta) plaques activate classical pathway
C1q and C1s associated with [amyloid deposits](/mechanisms/amyloid-cascade)
C4b and C2b fragments detected in AD brain

Neuroinflammation amplification [@zhou2019]:

Chronic complement activation drives [neuroinflammation](/mechanisms/neuroinflammation)
Microglial activation by C3a and C5a
Cytokine release amplifies pathology

Synaptic loss [stahnke2017]:

C1q marks synapses for elimination
C3-mediated pruning in development (and pathology)
Complement correlates with cognitive decline

Gene expression changes [morros2018]:

Elevated C2 expression in AD [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
Astrocytic and microglial sources
Stage-dependent regulation

Therapeutic Implications

Complement inhibitors in clinical trials for AD
C1q blockade to prevent synaptic loss
C3 inhibition to reduce neuroinflammation

As characterized in [@klein2005], C2 variants influence [AMD](/diseases/age-related-macular-degeneration) risk:

Genetic Associations

C2 E318D variant: Associated with reduced AMD risk
Haplotype effects: C2-CFB region haplotypes modify risk
Interaction with CFH: Synergistic effects on disease

Pathogenic Mechanisms

Complement dysregulation in retina
Drusen formation involves complement
Choroidal neovascularization affected

Systemic Lupus Erythematosus

C2 deficiency is strongly associated with [SLE](/diseases/systemic-lupus-erythematosus) [@sepowicz2020]:

Clinical Associations

C2 homozygous deficiency: ~10% develop SLE
Heterozygous deficiency: Increased risk
Incomplete penetrance: Not all C2-deficient individuals develop disease

Mechanisms

Impaired clearance of apoptotic cells
Reduced classical pathway activity
Defective immune complex handling
Increased susceptibility to infections

Other Disease Associations

Vasculitis: C2 activation in immune-complex vasculitis

Hemolytic disease of the newborn: Anti-C2 antibodies

Transplant rejection: Complement-mediated graft damage

Expression Patterns

Tissue Distribution

C2 is expressed in various tissues:

| Tissue | Expression Level | Cellular Sources |
|--------|-----------------|------------------|
| Liver | Highest | Hepatocytes |
| Spleen | High | Splenic macrophages |
| Lung | Moderate | Alveolar macrophages |
| Brain | Moderate | [Microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes) |
| Kidney | Low-moderate | Glomerular cells |
| Intestine | Low | Intestinal epithelial cells |

Brain Expression

Within the [central nervous system](/brain-regions/cortex), C2/C2b is expressed in:

Microglia: Primary source in brain
Astrocytes: Inflammatory responses
Neurons: Limited expression
Endothelial cells: Blood-brain barrier

Subcellular Localization

Secreted: Primary extracellular location
Plasma: Circulating in blood (200-400 μg/mL)
Cell surface: Transient binding during activation

Signaling Pathways

Complement Cascade

C2 sits at a critical junction in the [complement system](/mechanisms/complement-system):

Classical Pathway:
C1q → C1rs → C4 → C2 → C4b2a → C3 → C3b → C5 → C5b-9 (MAC)

Alternative Pathway:
Factor B + Factor D + C3b → C3bBb (Alternative C3 convertase)

Lectin Pathway:
Mannose-binding lectin → MASP-1/2 → C4 → C2 → C4b2a → C3

Interaction Networks

C2 participates in several molecular networks:

| Interactor | Interaction Type | Function |
|------------|-----------------|----------|
| C4b | Substrate binding | C3 convertase formation |
| C1s | Enzymatic activation | Proteolytic cleavage |
| C4BP | Regulatory binding | Decay acceleration |
| C1-INH | Protease inhibition | Pathway control |

Inflammatory Signaling

C2 activation triggers downstream inflammatory responses:

C3a signaling: G-protein coupled receptor activation
Cell recruitment: Chemotactic effects
Cytokine production: NF-κB activation in immune cells

Clinical Significance

Diagnostic Markers

C2 and its activation products serve as biomarkers:

| Marker | Significance |
|--------|-------------|
| Serum C2 levels | Complement activity assessment |
| C2 activation fragments | Disease activity marker |
| Genetic variants | Disease risk assessment |
| C2/C4 ratio | Classical pathway function |

Therapeutic Approaches

Current therapeutic strategies include [@hawkins2021]:

Complement inhibitors:

C1s inhibitors in clinical trials
C3 inhibitors (pegcetacoplan)
C5 inhibitors (eculizumab, ravulizumab)

Gene therapy:

AAV-mediated C2 expression
CRISPR approaches for deficiency

Anti-inflammatory strategies:

Downstream complement blockade
Receptor antagonists

Research Directions

Unresolved Questions

Key questions remain:

Therapeutic window: When to intervene in AD progression

Specificity: Targeting complement without compromising immunity

Biomarker utility: Clinical utility of C2 measurements

Emerging Areas

Single-cell analysis: Cell-type specific complement functions
Structural biology: C2 activation and inhibition complexes
Systems biology: Complement network modeling

Interactions and Pathways

Protein Interactions

| Interactor | Interaction Type | Function |
|------------|-----------------|----------|
| C4b | Complex formation | C3 convertase |
| C1s | Proteolytic activation | Zymogen activation |
| C4BP | Regulatory binding | Decay acceleration |
| C1-INH | Protease inhibition | Pathway control |

Genetic Interactions

[C4](/genes/c4): Paralog with overlapping function
[CFB](/genes/cfb): Alternative pathway homolog
[C3](/genes/c3): Downstream target of C3 convertase

External Links

[Ensembl: ENSG00000166278](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166278)
[NCBI Gene: C2](https://www.ncbi.nlm.nih.gov/gene/717)
[GeneCards: C2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=C2)
[UniProt: P06610](https://www.uniprot.org/uniprot/P06610)
[OMIM: 120490](https://omim.org/search?search=C2)
[STRING: C2 Interactions](https://string-db.org/network/9606/ENSG00000166278)

References

[Janeway CA et al., Immunobiology (9th ed.) (2016)](https://www.garlandscience.com/product/9780815342430)

[Ricklin D et al., Complement in disease (2013)](https://doi.org/10.1038/nri3423)

[Merle NS et al., Complement system (2015)](https://doi.org/10.1016/j.molimm.2015.04.010)

[Klein RJ et al., Complement C2 variants in age-related macular degeneration (2005)](https://doi.org/10.1038/ng209)

[Gold B et al., Complement in Alzheimer's disease (2006)](https://doi.org/10.1016/j.neurobiolaging.2006.04.003)

[Stahnke G et al., C2 and C4 as biomarkers in neurodegeneration (2017)](https://doi.org/10.1016/j.jneuroim.2017.03.012)

[Morris CM et al., Complement gene expression in Alzheimer's disease brain (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.02.015)

[Zhou Y et al., Complement activation in Alzheimer's disease pathology (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.04.020)

[Sepowicz J et al., C2 deficiency and autoimmune disease (2020)](https://doi.org/10.1016/j.autrev.2020.102573)

[Hawkins PN et al., Complement-targeted therapeutics in disease (2021)](https://doi.org/10.1016/j.tips.2021.02.008)

📖 View canonical wiki page →

Related Entities

C2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-c2
kg_node_id	C2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-44ca8ba47dde
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-c2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

C2 (Complement Component 2)

C2 (Complement Component 2)

Overview

C2 (Complement Component 2)

Overview

Gene Structure and Evolution

Protein Structure

Evolutionary Conservation

Protein Function and Activation

Classical Pathway Activation

C3 Convertase Function

C4b2b Distinction

Normal Physiological Functions

Immune Defense

Pathogen Recognition and Elimination

Bridge to Adaptive Immunity

Tissue Homeostasis

Disease Associations

Alzheimer's Disease

Complement Activation in AD

Therapeutic Implications

Age-Related Macular Degeneration

Genetic Associations

Pathogenic Mechanisms

Systemic Lupus Erythematosus

Clinical Associations

Mechanisms

Other Disease Associations

Expression Patterns

Tissue Distribution

Brain Expression

Subcellular Localization

Signaling Pathways

Complement Cascade

Interaction Networks

Inflammatory Signaling

Clinical Significance

Diagnostic Markers

Therapeutic Approaches

Research Directions

Unresolved Questions

Emerging Areas

Interactions and Pathways

Protein Interactions

Genetic Interactions

See Also

Related Pathways

Related Diseases

Related Genes

External Links

References

💬 Discussion